{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:16:33Z","timestamp":1788243393132,"version":"build-2803163510"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40265-026-02357-3","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:41:21Z","timestamp":1783946481000},"page":"1421-1434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-Acting Lipoglycopeptide Treatment of Invasive Gram-Positive Infections"],"prefix":"10.1007","volume":"86","author":[{"given":"Madison E.","family":"Salam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Chastain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Fish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s F.","family":"Henao-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Krsak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Morrisette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1746-7462","authenticated-orcid":false,"given":"Martin","family":"Krsak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"issue":"4","key":"2357_CR1","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1089\/sur.2020.436","volume":"22","author":"TM Duane","year":"2021","unstructured":"Duane TM, Huston JM, Collom M, Beyer A, Parli S, Buckman S, et al. Surgical Infection Society 2020 updated guidelines on the management of complicated skin and soft tissue infections. Surg Infect. 2021;22(4):383\u201399. https:\/\/doi.org\/10.1089\/sur.2020.436.","journal-title":"Surg Infect"},{"key":"2357_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/QCO.0000000000000989","volume":"37","author":"A Burillo","year":"2024","unstructured":"Burillo A, Pulido-Perez A, Bouza E. Current challenges in acute bacterial skin infection management. Curr Opin Infect Dis. 2024;37:71\u20139. https:\/\/doi.org\/10.1097\/QCO.0000000000000989.","journal-title":"Curr Opin Infect Dis"},{"issue":"8","key":"2357_CR3","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.cmi.2022.03.015","volume":"28","author":"AD Bai","year":"2022","unstructured":"Bai AD, Lo CKL, Komorowski AS, Suresh M, Guo K, Garg A, et al. Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis. Clin Microbiol Infect. 2022;28(8):1076\u201384. https:\/\/doi.org\/10.1016\/j.cmi.2022.03.015.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"2357_CR4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/21505594.2021.1878688","volume":"12","author":"GYC Cheung","year":"2021","unstructured":"Cheung GYC, Bae JS, Otto M. Pathogenicity and virulence of Staphylococcus aureus. Virulence. 2021;12(1):547\u201369. https:\/\/doi.org\/10.1080\/21505594.2021.1878688.","journal-title":"Virulence"},{"issue":"10369","key":"2357_CR5","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/S0140-6736(22)02185-7","volume":"400","author":"Collaborators GBDAR","year":"2022","unstructured":"Collaborators GBDAR. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;400(10369):2221\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(22)02185-7.","journal-title":"Lancet"},{"issue":"2","key":"2357_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40121-017-0156-z","volume":"6","author":"CL Stewart","year":"2017","unstructured":"Stewart CL, Turner MS, Frens JJ, Snider CB, Smith JR. Real-world experience with oritavancin therapy in invasive Gram-positive infections. Infect Dis Ther. 2017;6(2):277\u201389. https:\/\/doi.org\/10.1007\/s40121-017-0156-z.","journal-title":"Infect Dis Ther"},{"key":"2357_CR7","unstructured":"Dalvance\u00a0(dalbavancin) product prescribing information. North Chicago, Illinois, USA: Abbvie, Inc.; 2025. Available at:\u00a0DALVANCE label.\u00a0Accessed 1 Nov 2025."},{"key":"2357_CR8","unstructured":"Kimyrsa\u00a0(oritavancin) product prescribing\u00a0information. Parsippany, New Jersey, USA: Melinta\u00a0Therapeutics, LLC; 2025. Available at:\u00a0label.\u00a0Accessed 1 Nov 2025"},{"key":"2357_CR9","unstructured":"Orbactive\u00a0(oritavancin) product prescribing information. Parsippany, New Jersey, USA: Melinta\u00a0Therapeutics, LLC; 2025 Available at:\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/206334s006lbl.pdf.\u00a0Accessed 1 Nov 2025"},{"issue":"5","key":"2357_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac090","volume":"9","author":"RK Hoover","year":"2022","unstructured":"Hoover RK, Krsak M, Molina KC, Shah K, Redell M. Kimyrsa, an oritavancin-containing product: clinical study and review of properties. Open Forum Infect Dis. 2022;9(5):ofac090. https:\/\/doi.org\/10.1093\/ofid\/ofac090.","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"2357_CR11","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","volume":"70","author":"GG Zhanel","year":"2010","unstructured":"Zhanel GG, Calic D, Schweizer F, Zelenitsky S, Adam H, Lagac\u00e9-Wiens PR, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs. 2010;70(7):859\u201386.","journal-title":"Drugs"},{"issue":"10","key":"2357_CR12","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1093\/jac\/dky235","volume":"73","author":"MA Pfaller","year":"2018","unstructured":"Pfaller MA, Mendes RE, Duncan LR, Flamm RK, Sader HS. Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015\u201316. J Antimicrob Chemother. 2018;73(10):2748\u201356.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"2357_CR13","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s10096-022-04437-0","volume":"41","author":"HS Sader","year":"2022","unstructured":"Sader HS, Castanheira M, Huband MD, Shortridge D, Carvalhaes CG, Mendes RM. Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018-2020). Eur J Clin Microbiol Infect Dis. 2022;41(5):867\u201373.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"8","key":"2357_CR14","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1080\/1120009X.2023.2259673","volume":"35","author":"MA Pfaller","year":"2023","unstructured":"Pfaller MA, Mendes RE, Sader HS, Castanheira M, Carvalhaes CG. Oritavancin in vitro activity against Gram-positive organisms from European medical centers: a 10-year longitudinal overview from the SENTRY Antimicrobial Surveillance Program (2010-2019). J Chemother. 2023;35(8):689\u201399.","journal-title":"J Chemother"},{"issue":"2","key":"2357_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.diagmicrobio.2018.01.029","volume":"91","author":"MA Pfaller","year":"2018","unstructured":"Pfaller MA, Sader HS, Flamm RK, Castanheira M, Mendes RE. Oritavancin in vitro activity against Gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014. Diagn Microbiol Infect Dis. 2018;91(2):199\u2013204.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"11","key":"2357_CR16","doi-asserted-by":"publisher","first-page":"4762","DOI":"10.1128\/AAC.00952-09","volume":"53","author":"FF Arhin","year":"2009","unstructured":"Arhin FF, Draghi DC, Pillar CM, Parr TR Jr, Moeck G, Sahm DF. Comparative in vitro activity profile of oritavancin against recent Gram-positive clinical isolates. Antimicrob Agents Chemother. 2009;53(11):4762\u201371.","journal-title":"Antimicrob Agents Chemother"},{"key":"2357_CR17","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation\u00a0and Research; Coderre P. Clinical Microbiology Review: NDA 021883 Orig1s000.\u00a0Durata\u00a0Therapeutics Inc; February\u00a020, 2014. Accessed 10 January 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/021883Orig1s000MicroR.pdf"},{"issue":"5","key":"2357_CR18","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ijantimicag.2010.06.044","volume":"36","author":"F Campanile","year":"2010","unstructured":"Campanile F, Borbone S, Perez M, Bongiorno D, Cafiso V, Bertuccio T, et al. Heteroresistance to glycopeptides in Italian meticillin-resistant Staphylococcus aureus (MRSA) isolates. Int J Antimicrob Agents. 2010;36(5):415\u20139. https:\/\/doi.org\/10.1016\/j.ijantimicag.2010.06.044. (Epub 2010 Aug 19. PMID: 20727722).","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"2357_CR19","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1086\/527392","volume":"46","author":"DM Sievert","year":"2008","unstructured":"Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis. 2008;46(5):668\u201374. https:\/\/doi.org\/10.1086\/527392. (PMID: 18257700).","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2357_CR20","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1179\/joc.2005.17.6.593","volume":"17","author":"RN Jones","year":"2005","unstructured":"Jones RN, Fritsche TR, Sader HS, Goldstein BP. Antimicrobial spectrum and potency of Dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol. J Chemother. 2005;17(6):593\u2013600. https:\/\/doi.org\/10.1179\/joc.2005.17.6.593. (PMID: 16433188).","journal-title":"J Chemother"},{"key":"2357_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.00553","volume":"11","author":"M \u017diemyt\u0117","year":"2020","unstructured":"\u017diemyt\u0117 M, Rodr\u00edguez-D\u00edaz JC, Ventero MP, Mira A, Ferrer MD. Effect of Dalbavancin on staphylococcal biofilms when administered alone or in combination with biofilm-detaching compounds. Front Microbiol. 2020;11:553. https:\/\/doi.org\/10.3389\/fmicb.2020.00553. (PMID: 32362877; PMCID: PMC7180179).","journal-title":"Front Microbiol"},{"issue":"8","key":"2357_CR22","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1128\/AAC.43.8.1875","volume":"43","author":"M Arthur","year":"1999","unstructured":"Arthur M, Depardieu F, Reynolds P, Courvalin P. Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci. Antimicrob Agents Chemother. 1999;43(8):1875\u201380. https:\/\/doi.org\/10.1128\/AAC.43.8.1875. (PMID: 10428906; PMCID: PMC89384).","journal-title":"Antimicrob Agents Chemother"},{"key":"2357_CR23","unstructured":"Barrett JF.\u00a0Oritavancin. Eli Lilly & Co. Curr\u00a0Opin\u00a0Investig\u00a0Drugs. 2001;2(8):1039-44"},{"issue":"3","key":"2357_CR24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2165\/00003495-200262030-00002","volume":"62","author":"PK Linden","year":"2002","unstructured":"Linden PK. Treatment options for vancomycin-resistant enterococcal infections. Drugs. 2002;62(3):425\u201341. https:\/\/doi.org\/10.2165\/00003495-200262030-00002. (PMID: 11827558).","journal-title":"Drugs"},{"issue":"4","key":"2357_CR25","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.idc.2020.08.004","volume":"34","author":"WR Miller","year":"2020","unstructured":"Miller WR, Murray BE, Rice LB, Arias CA. Resistance in vancomycin-resistant enterococci. Infect Dis Clin North Am. 2020;34(4):751\u201371. https:\/\/doi.org\/10.1016\/j.idc.2020.08.004. (PMID: 33131572; PMCID: PMC7640809).","journal-title":"Infect Dis Clin North Am"},{"issue":"3","key":"2357_CR26","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1128\/AAC.48.3.940-945.2004","volume":"48","author":"A Leighton","year":"2004","unstructured":"Leighton A, Gottlieb AB, Dorr MB, Jabes D, Mosconi G, VanSaders C, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous Dalbavancin in healthy volunteers. Antimicrob Agents Chemother. 2004;48(3):940\u20135. https:\/\/doi.org\/10.1128\/AAC.48.3.940-945.2004. (PMID: 14982787; PMCID: PMC353075).","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2357_CR27","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1093\/jac\/dkl311","volume":"58","author":"KE Bowker","year":"2006","unstructured":"Bowker KE, Noel AR, MacGowan AP. Pharmacodynamics of Dalbavancin studied in an in vivo pharmacokinetic system. J Antimicrob Chemother. 2006;58(4):802\u20135.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"2357_CR28","doi-asserted-by":"publisher","first-page":"7833","DOI":"10.1128\/AAC.01717-15","volume":"59","author":"A Lepak","year":"2015","unstructured":"Lepak A, Marchillo K, VanHecker J, Andes D. Impact of glycopeptide resistance in Staphylococcus aureus on the Dalbavancin in vivo pharmacodynamic target. Antimicrob Agents Chemother. 2015;59(12):7833\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2357_CR29","first-page":"e02260","volume":"65","author":"PG Cojutti","year":"2023","unstructured":"Cojutti PG, Rinaldi M, Zamparini E, Rossi N, Tedeschi S, Conti M, et al. Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections. Antimicrob Agents Chemother. 2023;65(5):e02260-e2320.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2357_CR30","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1128\/AAC.47.5.1700-1706.2003","volume":"47","author":"CJ Boylan","year":"2003","unstructured":"Boylan CJ, Campanale K, Iversen PW, Phillips DL, Zeckel ML, Parr TR Jr. Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother. 2003;47(5):1700\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2357_CR31","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1128\/AAC.50.3.994-1000.2006","volume":"50","author":"SM Bhavnani","year":"2006","unstructured":"Bhavnani SM, Passarell JA, Owen JS, Loutit JS, Porter SB, Ambrose PG. Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2006;50(3):994\u20131000.","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl_1","key":"2357_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw172.1506","volume":"3","author":"J Chaisson","year":"2016","unstructured":"Chaisson J, White R. Comparison of dalbavancin, oritavancin and vancomycin pharmacodynamics using clinical targets against ABSSSI pathogens. Open Forum Infect Dis. 2016;3(suppl_1):1958. https:\/\/doi.org\/10.1093\/ofid\/ofw172.1506.","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl 1","key":"2357_CR33","first-page":"36","volume":"7","author":"WE Rose","year":"2020","unstructured":"Rose WE, Hutson PR. A two-dose oritavancin regimen using pharmacokinetic estimation analysis. Drugs. 2020;7(Suppl 1):36\u201340.","journal-title":"Drugs"},{"key":"2357_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijid.2023.11.003","volume":"138","author":"M Su\u00e1rez","year":"2024","unstructured":"Su\u00e1rez M, P\u00e9rez-Landeiro A, Sanjurjo A, Lima O, Sousa A, L\u00f3pez A, et al. Comparison of dalbavancin with standard of care in the management of infective endocarditis: efficacy, safety, and cost analysis. Int J Infect Dis. 2024;138:41\u20135.","journal-title":"Int J Infect Dis"},{"issue":"2","key":"2357_CR35","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1093\/ajhp\/zxae025","volume":"81","author":"D Donnelly","year":"2024","unstructured":"Donnelly D, Pillinger KE, Debnath A, DePasquale W, Munsiff S, Louie T, et al. Cost evaluation\u00a0of continuation\u00a0of therapy with dalbavancin compared to standard-of-care antibiotics alone in hospitalized persons who inject drugs with severe Gram-positive infections. Am J Health Syst Pharm. 2024;81(2):S40\u20138.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"2357_CR36","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02385-22","volume":"11","author":"R Lueking","year":"2023","unstructured":"Lueking R, Wei W, Mang NS, Ortwine JK, Meisner J. Evaluation of dalbavancin use on clinical outcomes, cost-savings, and adherence at a large safety net hospital. Microbiol Spectr. 2023;11(1):e0238522.","journal-title":"Microbiol Spectr."},{"issue":"8","key":"2357_CR37","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1093\/jac\/dkz162","volume":"74","author":"T Morrisette","year":"2019","unstructured":"Morrisette T, Miller MA, Montague BT, Barber GR, McQueen RB, Krsak M. On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections. J Antimicrob Chemother. 2019;74(8):2405\u201316. https:\/\/doi.org\/10.1093\/jac\/dkz162.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"2357_CR38","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/phar.2389","volume":"40","author":"M Krsak","year":"2020","unstructured":"Krsak M, Morrisette T, Miller M, Molina K, Huang M, Damioli L, et al. Advantages of outpatient treatment with long-acting lipoglycopeptides for serious Gram-positive infections: a review. Pharmacotherapy. 2020;40(5):469\u201378.","journal-title":"Pharmacotherapy"},{"issue":"Suppl 2","key":"2357_CR39","first-page":"5416","volume":"9","author":"BT Alexander","year":"2022","unstructured":"Alexander BT, Miller MM, LeMaster M, Bergman SJ, Van Schooneveld TC, Cortes-Penfield NW. Clinical outcomes and cost savings of dalbavancin use in OPAT: focus on complicated Staphylococcus aureus infections. Open Forum Infec Dis. 2022;9(Suppl 2):5416\u20137.","journal-title":"Open Forum Infec Dis."},{"issue":"3","key":"2357_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106069","volume":"56","author":"G Thomas","year":"2020","unstructured":"Thomas G, Henao-Mart\u00ednez AF, Franco-Paredes C, Chastain DB. Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: a systematic review. Int J Antimicrob Agents. 2020;56(3):106069.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"2357_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2025.107581","volume":"66","author":"D Salvatore","year":"2025","unstructured":"Salvatore D, Moore J, Steuber TD. Long-acting lipoglycopeptides compared to standard-of-care for the treatment of complicated Gram-positive infections: a systematic review and meta-analysis. Int J Antimicrob Agents. 2025;66(5):107581.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"2357_CR42","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.11641","volume":"8","author":"D Goodman-Meza","year":"2025","unstructured":"Goodman-Meza D, Weiss RE, Poimboeuf ML, Feng J, Vijayan T, Martinello M, et al. Comparative effectiveness of long-acting lipoglycopeptides vs standard-of-care antibiotics in serious bacterial infections. JAMA Netw Open. 2025;8(5):e2511641.","journal-title":"JAMA Netw Open"},{"issue":"7","key":"2357_CR43","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/ofid\/ofac335","volume":"9","author":"KC Molina","year":"2022","unstructured":"Molina KC, Lunowa C, Lebin M, Segerstrom Nunez A, Azimi SF, Krsak M, et al. Comparison\u00a0of sequential dalbavancin with\u00a0standard-of-care treatment for Staphylococcus aureus bloodstream infections. Open Forum Infect Dis. 2022;9(7):335.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"2357_CR44","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1086\/427283","volume":"40","author":"I Raad","year":"2005","unstructured":"Raad I, Darouiche R, Vazquez J, Lentnek A, Hachem R, Hanna H, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin Infect Dis. 2005;40(3):374\u201380. https:\/\/doi.org\/10.1086\/427283. (Epub 2005 Jan 7. PMID: 15668859.).","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2357_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab486","volume":"8","author":"MM Cooper","year":"2021","unstructured":"Cooper MM, Preslaski CR, Shihadeh KC, Hawkins KL, Jenkins TC. Multiple-dose dalbavancin regimens as the predominant treatment of deep-seated or endovascular infections: a scoping review. Open Forum Infect Dis. 2021;8(11):ofab486. https:\/\/doi.org\/10.1093\/ofid\/ofab486.","journal-title":"Open Forum Infect Dis"},{"key":"2357_CR46","volume":"13","author":"NA Turner","year":"2025","unstructured":"Turner NA, Hamasaki T, Doernberg SB, Lodise TP, King HA, Ghazaryan V, et al. Dalbavancin for treatment of Staphylococcus aureus bacteremia: the DOTS randomized clinical trial. JAMA. 2025;13:e2512543.","journal-title":"JAMA"},{"issue":"6","key":"2357_CR47","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/ofid\/ofae315","volume":"11","author":"CF Volk","year":"2024","unstructured":"Volk CF, Hutson PR, Rose WE. Simulated target attainment of multidose regimens of dalbavancin for prolonged durations of therapy. Open Forum Infect Dis. 2024;11(6):315.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"2357_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106918","volume":"62","author":"C Hidalgo-Tenorio","year":"2023","unstructured":"Hidalgo-Tenorio C, Sadyrbaeva-Dolgova S, Enr\u00edquez-G\u00f3mez A, Mu\u00f1oz P, Plata-Ciezar A, Mir\u00f3 JM, et al. EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential\/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci. Int J Antimicrob Agents. 2023;62(3):106918. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106918.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"2357_CR49","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s15010-024-02393-9","volume":"53","author":"GM Leanza","year":"2025","unstructured":"Leanza GM, Rando E, Frondizi F, Taddei E, Giovannenze F, Horcajada JP, et al. A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis. Infection. 2025;53(1):15\u201323. https:\/\/doi.org\/10.1007\/s15010-024-02393-9.","journal-title":"Infection"},{"issue":"11","key":"2357_CR50","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.3390\/antibiotics10111296","volume":"10","author":"M de Pablo-Mir\u00f3","year":"2021","unstructured":"de Pablo-Mir\u00f3 M, Pujol-Ruiz S, Iftimie S, Arenas-Miras MDM, L\u00f3pez-Montesinos I, Duran-Jord\u00e0 X, et al. Comparative analysis of dalbavancin versus other antimicrobial options for Gram-positive cocci infections: effectiveness, hospital stay and mortality. Antibiotics (Basel). 2021;10(11):1296.","journal-title":"Antibiotics (Basel)."},{"issue":"5","key":"2357_CR51","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ijantimicag.2019.08.006","volume":"54","author":"A Dinh","year":"2019","unstructured":"Dinh A, Duran C, Pavese P, Khatchatourian L, Monnin B, Bleibtreu A, et al. French national cohort of first use of dalbavancin: a high proportion of off-label use. Int J Antimicrob Agents. 2019;54(5):668\u201372.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"2357_CR52","doi-asserted-by":"publisher","first-page":"334","DOI":"10.37201\/req\/012.2024","volume":"37","author":"D Brandariz-N\u00fa\u00f1ez","year":"2024","unstructured":"Brandariz-N\u00fa\u00f1ez D, Luances-Rodr\u00edguez A, Feijoo-Vilanova P, Guti\u00e9rrez-Urb\u00f3n JM, Ramudo-Cela L, Mart\u00edn-Herranz MI, et al. Dalbavancin as consolidation therapy for infective endocarditis in patients with comorbidity. A real world experience. Rev Esp Quimioter. 2024;37(4):334\u201340.","journal-title":"Rev Esp Quimioter"},{"issue":"5","key":"2357_CR53","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/cid\/ciy279","volume":"67","author":"S Tobudic","year":"2018","unstructured":"Tobudic S, Forstner C, Burgmann H, Lagler H, Ramharter M, Steininger C, et al. Dalbavancin as primary and sequential treatment for Gram-positive infective endocarditis: 2-year experience at the General Hospital of Vienna. Clin Infect Dis. 2018;67(5):795\u20138.","journal-title":"Clin Infect Dis"},{"key":"2357_CR54","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ijid.2019.02.013","volume":"81","author":"S Wunsch","year":"2019","unstructured":"Wunsch S, Krause R, Valentin T, Prattes J, Janata O, Lenger A, et al. Multicenter clinical experience of real life dalbavancin use in Gram-positive infections. Int J Infect Dis. 2019;81:210\u20134.","journal-title":"Int J Infect Dis"},{"issue":"2","key":"2357_CR55","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.eimce.2024.04.012","volume":"43","author":"E Aparicio-Minguij\u00f3n","year":"2025","unstructured":"Aparicio-Minguij\u00f3n E, Bo\u00e1n J, Terr\u00f3n A, Heredia C, Puente C, P\u00e9rez-Jacoiste As\u00edn A, et al. Dalbavancin as sequential therapy in infective endocarditis: real-life experience in elder and comorbid patients. Enfermedades infecciosas y microbiologia clinica (English ed). 2025;43(2):86\u201392.","journal-title":"Enfermedades infecciosas y microbiologia clinica (English ed.)"},{"issue":"4","key":"2357_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106945","volume":"62","author":"J Courjon","year":"2023","unstructured":"Courjon J, Senneville E, Illes HG, Pavese P, Boutoille D, Daoud FC, et al. Effectiveness and safety of dalbavancin in France: a prospective, multicentre cohort study. Int J Antimicrob Agents. 2023;62(4):106945.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"2357_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106210","volume":"56","author":"MP Veve","year":"2020","unstructured":"Veve MP, Patel N, Smith ZA, Yeager SD, Wright LR, Shorman MA. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections. Int J Antimicrob Agents. 2020;56(6):106210.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"2357_CR58","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12879-023-08725-8","volume":"24","author":"WM Texidor","year":"2024","unstructured":"Texidor WM, Miller MA, Molina KC, Krsak M, Calvert B, Hart C, et al. Oritavancin as sequential therapy for Gram-positive bloodstream infections. BMC Infect Dis. 2024;24(1):127.","journal-title":"BMC Infect Dis"},{"issue":"7","key":"2357_CR59","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/ofid\/ofaf333","volume":"12","author":"H Jordan","year":"2025","unstructured":"Jordan H, Kozierowski K, Pickles R, Davis JS. Oritavancin\u00a0for the treatment of Staphylococcus aureus bacteremia-A retrospective single-arm cohort study. Open Forum Infect Dis. 2025;12(7):333.","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"2357_CR60","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/ofid\/ofaf416","volume":"12","author":"F Frondizi","year":"2025","unstructured":"Frondizi F, Leanza GM, Chiuchiarelli M, Catania F, Sangiorgi F, Giovannenze F, et al. The use of oritavancin\u00a0as consolidation\u00a0therapy for infective endocarditis caused by Enterococcus spp. Open Forum Infect Dis. 2025;12(8):416.","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"2357_CR61","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01024-19","volume":"63","author":"U Rappo","year":"2019","unstructured":"Rappo U, Dunne MW, Puttagunta S, Baldassarre JS, Su S, Desai-Krieger D, et al. Epithelial lining fluid and plasma concentrations of dalbavancin in healthy adults after a single 1,500-milligram infusion. Antimicrob Agents Chemother. 2019;63(11):e01024-19. https:\/\/doi.org\/10.1128\/AAC.01024-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 3","key":"2357_CR62","doi-asserted-by":"publisher","first-page":"S220","DOI":"10.1093\/cid\/cis001","volume":"54","author":"PG Ambrose","year":"2012","unstructured":"Ambrose PG, Drusano GL, Craig WA. In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans. Clin Infect Dis. 2012;54(Suppl 3):S220\u20138.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2357_CR63","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4103\/jpp.JPP_2_17","volume":"8","author":"KE Barber","year":"2017","unstructured":"Barber KE, Tirmizi A, Finley R, Stover KR. Dalbavancin use for the treatment of methicillin-resistant Staphylococcus aureus pneumonia. J Pharmacol Pharmacother. 2017;8(2):77\u20139.","journal-title":"J Pharmacol Pharmacother"},{"issue":"4","key":"2357_CR64","doi-asserted-by":"publisher","first-page":"A1635","DOI":"10.1016\/j.chest.2024.06.1033","volume":"166","author":"AM Andaya","year":"2024","unstructured":"Andaya AM, Chaparala W. Bilateral MRSA pneumonia presenting as pulmonary mass-like nodularities in a middle-aged female with history of benign breast mass. Chest. 2024;166(4):A1635-1636.","journal-title":"Chest"},{"issue":"4","key":"2357_CR65","doi-asserted-by":"publisher","first-page":"A1157","DOI":"10.1016\/j.chest.2023.07.834","volume":"164","author":"A Othman","year":"2023","unstructured":"Othman A, Shastri DD, Peshin S, Kommineni RD, Vedantam V. A case of incidental lung abscess caused by methicillin-resistant Staphylococcus aureus. Chest. 2023;164(4):A1157-1158.","journal-title":"Chest"},{"issue":"4","key":"2357_CR66","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1128\/AAC.04550-14","volume":"59","author":"MW Dunne","year":"2015","unstructured":"Dunne MW, Puttagunta S, Sprenger CR, Rubino C, Van Wart S, Baldassarre J. Extended-duration dosing and distribution of Dalbavancin into bone and articular tissue. Antimicrob Agents Chemother. 2015;59(4):1849\u201355. https:\/\/doi.org\/10.1128\/AAC.04550-14.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"2357_CR67","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.1007\/s00590-023-03609-8","volume":"33","author":"JB Doub","year":"2023","unstructured":"Doub JB, Alkayali T, Amoroso A, Nandi S, Talwani R. Effective use of a two-dose regimen of dalbavancin to treat prosthetic joint infections and spinal hardware infections. Eur J Orthop Surg Traumatol. 2023;33(8):3655\u20139.","journal-title":"Eur J Orthop Surg Traumatol"},{"issue":"4","key":"2357_CR68","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","volume":"51","author":"E Bouza","year":"2018","unstructured":"Bouza E, Valerio M, Soriano A, Morata L, Carus EG, Rodr\u00edguez-Gonz\u00e1lez C, et al. Dalbavancin in the treatment of different Gram-positive infections: a real-life experience. Int J Antimicrob Agents. 2018;51(4):571\u20137.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"2357_CR69","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/ofid\/ofy331","volume":"6","author":"U Rappo","year":"2018","unstructured":"Rappo U, Puttagunta S, Shevchenko V, Shevchenko A, Jandourek A, Gonzalez PL, et al. Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety. Open Forum Infect Dis. 2018;6(1):331.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"2357_CR70","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/jac\/dkl281","volume":"58","author":"CE Nord","year":"2006","unstructured":"Nord CE, Rasmanis G, Wahlund E. Effect of dalbavancin on the normal intestinal microflora. J Antimicrob Chemother. 2006;58(3):627\u201331.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"2357_CR71","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ijantimicag.2018.11.023","volume":"53","author":"DB Chastain","year":"2019","unstructured":"Chastain DB, Davis A. Treatment of chronic osteomyelitis with multidose oritavancin: a case series and literature review. Int J Antimicrob Agents. 2019;53(4):429\u201334.","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"2357_CR72","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/ofid\/ofz479","volume":"6","author":"M Redell","year":"2019","unstructured":"Redell M, Sierra-Hoffman M, Assi M, Bochan M, Chansolme D, Gandhi A, et al. The CHROME study, a real-world experience of single- and multiple-dose oritavancin\u00a0for treatment of Gram-positive infections. Open Forum Infect Dis. 2019;6(11):479.","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl 1","key":"2357_CR73","first-page":"41","volume":"7","author":"NW Van Hise","year":"2020","unstructured":"Van Hise NW, Chundi V, Didwania V, Anderson M, McKinsey D, Roig I, et al. Treatment of acute osteomyelitis with once-weekly oritavancin: a two-year, multicenter, retrospective study. Drugs. 2020;7(Suppl 1):41\u20135.","journal-title":"Drugs"},{"issue":"3","key":"2357_CR74","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40121-024-00925-2","volume":"13","author":"NW Van Hise","year":"2024","unstructured":"Van Hise NW, Petrak RM, Shah K, Diaz M, Chundi V, Redell M. Oritavancin versus daptomycin for osteomyelitis treatment after surgical debridement. Infect Dis Ther. 2024;13(3):535\u201347.","journal-title":"Infect Dis Ther"},{"issue":"7","key":"2357_CR75","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1097\/CORR.0000000000003449","volume":"483","author":"M Krsak","year":"2025","unstructured":"Krsak M, Morrisette T, Damioli L, Flues B, Liu EW, Zhou AY, et al. Can oritavancin be used for treatment and\/or suppressive antimicrobial therapy of bone and joint infections caused by vancomycin-resistant Enterococcus faecium. Clin Orthop Relat Res. 2025;483(7):1225\u201333.","journal-title":"Clin Orthop Relat Res"},{"issue":"11","key":"2357_CR76","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/phar.70072","volume":"45","author":"M Krsak","year":"2025","unstructured":"Krsak M, Klimpl D, Mueller SW, Morrisette T, Grimshaw AA, Chastain D, et al. Oritavancin for treatment of osteomyelitis: a systematic review and meta-analysis of observational studies. Pharmacotherapy. 2025;45(11):754\u201363. https:\/\/doi.org\/10.1002\/phar.70072.","journal-title":"Pharmacotherapy"},{"issue":"25","key":"2357_CR77","volume":"26","author":"JI Tegethoff","year":"2024","unstructured":"Tegethoff JI, Teitelbaum I, Kiser TH. Rapid and effective treatment of peritonitis in peritoneal dialysis patients with intravenous dalbavancin. Am J Case Rep. 2024;26(25):e942755.","journal-title":"Am J Case Rep."},{"issue":"5","key":"2357_CR78","doi-asserted-by":"crossref","first-page":"e02089","DOI":"10.1128\/AAC.02089-19","volume":"64","author":"ET Van Matre","year":"2020","unstructured":"Van Matre ET, Teitelbaum I, Kiser TH. intravenous and intraperitoneal pharmacokinetics of dalbavancin in peritoneal dialysis patients. Antimicrob Agents Chemother. 2020;64(5):e02089-e2119.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"2357_CR79","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1097\/INF.0000000000000646","volume":"34","author":"JS Bradley","year":"2015","unstructured":"Bradley JS, Puttagunta S, Rubino CM, Blumer JL, Dunne M, Sullivan JE. Pharmacokinetics, safety and tolerability of single dose dalbavancin in children 12-17 years of age. Pediatr Infect Dis J. 2015;34(7):748\u201352.","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"2357_CR80","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1097\/INF.0000000000001538","volume":"36","author":"D Gonzalez","year":"2017","unstructured":"Gonzalez D, Bradley JS, Blumer J, Yogev R, Watt KM, James LP, et al. Dalbavancin pharmacokinetics and safety in children 3 months to 11 years of age. Pediatr Infect Dis J. 2017;36(7):645\u201353.","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"2357_CR81","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/INF.0000000000003764","volume":"42","author":"TJ Carrothers","year":"2023","unstructured":"Carrothers TJ, Lagraauw HM, Lindbom L, Riccobene TA. Population pharmacokinetic and pharmacokinetic\/pharmacodynamic target attainment analyses for dalbavancin in pediatric patients. Pediatr Infect Dis J. 2023;42(2):99\u2013105.","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"2357_CR82","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/INF.0000000000003798","volume":"42","author":"M Giorgobiani","year":"2023","unstructured":"Giorgobiani M, Burroughs MH, Antadze T, Carrothers TJ, Riccobene TA, Patel R, et al. The safety and efficacy of dalbavancin and active comparator in pediatric patients with acute bacterial skin and skin structure infections. Pediatr Infect Dis J. 2023;42(3):199\u2013205.","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"2357_CR83","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1177\/08971900241285521","volume":"38","author":"T Morrisette","year":"2025","unstructured":"Morrisette T, Alghamdi S, Maree MB, Dixon TC, Thacker SA. One and done? An evaluation of the clinical outcomes of single- and multi-dose dalbavancin use in the pediatric population. J Pharm Pract. 2025;38(2):275\u20138.","journal-title":"J Pharm Pract"},{"issue":"8","key":"2357_CR84","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1093\/jac\/dkae212","volume":"79","author":"A Gamell","year":"2024","unstructured":"Gamell A, Velasco-Arnaiz E, L\u00f3pez-Ramos MG, R\u00edos-Barn\u00e9s M, Sim\u00f3-Nebot S, Fumad\u00f3 V, et al. Off-label use of dalbavancin in children: a case series. J Antimicrob Chemother. 2024;79(8):2062\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"2357_CR85","doi-asserted-by":"crossref","unstructured":"Guill\u00e9n-Mart\u00ednez M, Aguilera-Alonso D, Santos-P\u00e9rez JL, V\u00e1zquez-P\u00e9rez \u00c1, Ramos-Amador JT, Prieto Tato LM. Case series: off-label use of dalbavancin in pediatric gram-positive infections. Pediatr\u00a0Infect Dis\u00a0J. 2025.","DOI":"10.1097\/INF.0000000000004883"},{"issue":"10","key":"2357_CR86","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1128\/AAC.00231-09","volume":"53","author":"CM Rubino","year":"2009","unstructured":"Rubino CM, Van Wart SA, Bhavnani SM, Ambrose PG, McCollam JS, Forrest A. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob Agents Chemother. 2009;53(10):4422\u20138. https:\/\/doi.org\/10.1128\/AAC.00231-09.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"2357_CR87","doi-asserted-by":"publisher","first-page":"P25","DOI":"10.1186\/cc6246","volume":"12","author":"J Dowell","year":"2008","unstructured":"Dowell J, Seltzer E, Buckwalter M, Marbury T, Simoneau D, Boudry E. The pharmacokinetics of Dalbavancin in subjects with mild, moderate, or severe hepatic impairment. Crit Care. 2008;12(Suppl 2):P25. https:\/\/doi.org\/10.1186\/cc6246.","journal-title":"Crit Care"},{"issue":"4","key":"2357_CR88","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1177\/0091270008330162","volume":"49","author":"T Marbury","year":"2009","unstructured":"Marbury T, Dowell JA, Seltzer E, Buckwalter M. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment. J Clin Pharmacol. 2009;49(4):465\u201376. https:\/\/doi.org\/10.1177\/0091270008330162.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"2357_CR89","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1093\/ofid\/ofz274","volume":"6","author":"T Morrisette","year":"2019","unstructured":"Morrisette T, Miller MA, Montague BT, Barber GR, McQueen RB, Krsak M. Long-acting lipoglycopeptides: \u201clineless antibiotics\u201d for serious infections in persons who use drugs. Open Forum Infect Dis. 2019;6(7):274.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"2357_CR90","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40360-020-00452-z","volume":"21","author":"A Ahiskali","year":"2020","unstructured":"Ahiskali A, Rhodes H. Oritavancin for the treatment of complicated Gram-positive infection in persons who inject drugs. BMC Pharmacol Toxicol. 2020;21(1):73.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"Suppl 5","key":"2357_CR91","doi-asserted-by":"publisher","first-page":"S486","DOI":"10.1093\/infdis\/jiaa001","volume":"222","author":"M Krsak","year":"2020","unstructured":"Krsak M, Montague BT, Trowbridge P, Johnson SC, Binswanger IA. Opioid use and chronic infections: the value of addressing the syndemic in correctional settings via telemedicine guidance and broader use of long-acting medications. J Infect Dis. 2020;222(Suppl 5):S486\u201393.","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"2357_CR92","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1093\/ofid\/ofx163.114","volume":"4","author":"B Georgiades","year":"2017","unstructured":"Georgiades B, Rappo U, Gonzalez PL, McGregor JS, Chen J, McCarthy M. Efficacy and safety of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in the obese population. Open Forum Infect Dis. 2017;4(Suppl 1):S109\u201310.","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"2357_CR93","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/ofid\/ofad256","volume":"10","author":"T Riccobene","year":"2023","unstructured":"Riccobene T, Lock J, Lyles RD, Georgiades B, Nowak M, Gonzalez PL, et al. Dalbavancin for the treatment of acute bacterial\u00a0skin\u00a0and skin structure infection\u00a0in patients with\u00a0obesity\u00a0or\u00a0diabetes: a\u00a0subgroup\u00a0analysis\u00a0of\u00a0pooled\u00a0phase 3\u00a0clinical\u00a0trials. Open Forum Infect Dis. 2023;10(6):256.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"2357_CR94","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.jiac.2021.12.022","volume":"28","author":"H Ritchie","year":"2022","unstructured":"Ritchie H, Aggarwal A, Schimmel J, Lorenzo MP. Clinical failure of dalbavancin for MRSA bacteremia in patient with severe obesity and history of IVDU. J Infect Chemother. 2022;28(3):465\u20138.","journal-title":"J Infect Chemother"},{"issue":"11","key":"2357_CR95","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/ofid\/ofad411","volume":"10","author":"RP Moenster","year":"2023","unstructured":"Moenster RP, Wallace-Lacey A, Western H, Tiefenaur S, Abdulbasir A, Alberts J, et al. Oritavancin\u00a0vs standard of care for treatment\u00a0of\u00a0nonendovascular\u00a0Gram-positive bloodstream infections. Open Forum Infect Dis. 2023;10(11):411.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"2357_CR96","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3390\/antibiotics14020190","volume":"14","author":"G Baiardi","year":"2025","unstructured":"Baiardi G, Cameran Caviglia M, Boni S, Di Paolo A, Marini V, Cangemi G, et al. Multidose dalbavancin population pharmacokinetic analysis for prolonged target attainment in patients requiring long-term treatment. Antibiotics (Basel). 2025;14(2):190.","journal-title":"Antibiotics (Basel)."},{"issue":"2","key":"2357_CR97","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.cmi.2024.08.021","volume":"31","author":"V Galfo","year":"2025","unstructured":"Galfo V, Tiseo G, Riccardi N, Falcone M. Therapeutic drug monitoring of antibiotics for methicillin-resistant Staphylococcus aureus infections: an updated narrative review for clinicians. Clin Microbiol Infect. 2025;31(2):194\u2013200.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"2357_CR98","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01363-25","volume":"70","author":"H Sayadi","year":"2026","unstructured":"Sayadi H, Gregoire M, Fromage Y, Ksentini M, Labriffe M, Monchaud C, et al. Predicting prolonged dalbavancin exposure using machine learning: a validated strategy for individualized redosing. Antimicrob Agents Chemother. 2026;70(1):e0136325. https:\/\/doi.org\/10.1128\/aac.01363-25.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2357_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.107038","volume":"63","author":"PG Cojutti","year":"2024","unstructured":"Cojutti PG, Gatti M, Punt N, Dou\u0161a J, Zamparini E, Tedeschi S, et al. Implementation and validation of a Bayesian method for accurately forecasting duration of optimal pharmacodynamic target attainment with dalbavancin during long-term use for subacute and chronic staphylococcal infections. Int J Antimicrob Agents. 2024;63(1):107038. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.107038.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"2357_CR100","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00023-24","volume":"68","author":"D Cattaneo","year":"2024","unstructured":"Cattaneo D, Fusi M, Galli L, Genovese C, Giorgi R, Matone M, et al. Proactive therapeutic monitoring of dalbavancin concentrations in the long-term management of chronic osteoarticular\/periprosthetic joint infections. Antimicrob Agents Chemother. 2024;68(4):e0002324.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"2357_CR101","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1093\/jac\/dkad331","volume":"78","author":"C Hervochon","year":"2023","unstructured":"Hervochon C, Hennart B, Leroy AG, Corvec S, Boutoille D, Senneville \u00c9, et al. Dalbavancin plasma concentrations in 133 patients: a PK\/PD observational study. J Antimicrob Chemother. 2023;78(12):2919\u201325.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"2357_CR102","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01830-24","volume":"69","author":"PG Cojutti","year":"2025","unstructured":"Cojutti PG, Gatti M, Tedeschi S, Zamparini E, Meschiari M, Danzi M, et al. Usefulness of a hub and spoke TDM-guided expert clinical pharmacological advice program of dalbavancin for optimizing very long-term curative or suppressive treatment of chronic staphylococcal infections. Antimicrob Agents Chemother. 2025;69(4):e0183024.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"2357_CR103","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s10096-024-04844-5","volume":"43","author":"M Bongiovanni","year":"2024","unstructured":"Bongiovanni M, Thoueille P, Barda B, Mercier T, Marzolini C, Ramponi N, et al. Oritavancin use in patients with recurrent bone infections by methicillin-resistant Staphylococcus aureus with monitoring of concentrations. Eur J Clin Microbiol Infect Dis. 2024;43(7):1503\u20134.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2357_CR104","doi-asserted-by":"publisher","unstructured":"Lodise TP, Turner NA, Hamasaki T, Fishbane N, Ghazaryan V, Wall A, Ge L, Wu Q, Zeng L, Riccobene T, Patel R, Zaharoff S, Rappo U, Evans S, Fowler VG Jr, Chambers HF, Holland TL; Antibacterial Resistance Leadership Group. Pharmacokinetics of Dalbavancin in complicated Staphylococcus aureus bacteremia: a secondary analysis of the DOTS randomized clinical trial. JAMA Netw Open. 2026;9(4):e2611652. https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.11652.","DOI":"10.1001\/jamanetworkopen.2026.11652"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02357-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02357-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02357-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:03:05Z","timestamp":1788242585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02357-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":104,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2357"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02357-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No\u00a0funding was received for the publication of this article.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Douglas Fish will be receiving research support from Melinta Therapeutics (ORI maker) to study razafungin. Taylor Morrisette is currently receiving grant funding through AbbVie Inc. (DAL maker) and has participated in scientific advisory boards for AbbVie Inc. Scott Mueller is conducting a US Department of Defense-funded study with DAL. Martin Krsak previously received material research support from AbbVie, Inc. (maker of DAL) and a small teaching reimbursement for IDWeek 2022 session on Kimyrsa (ORI). Other co-authors (A.H.\/M.S.\/D.C.\/M.i.K.\/M.M.) report no competing interests relevant to this work.","order":2,"name":"Ethics","label":"Conflicts of Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics\/IRB Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors sufficiently contributed to literature review, data curation, synthesis, and presentation.","order":8,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}